Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: T-cell immunoreceptor with Ig and ITIM domain (TIGIT) blockade could represent an alternative therapeutic option to release the immune response in patients with multiple myeloma. Here we analyzed the expression of TIGIT and its ligands poliovirus receptor (PVR) and nectin-2 in the bone marrow (BM) of patients with monoclonal gammopathies and the efficacy of TIGIT blockade activating antimyeloma immunity. Experimental Design: Expression levels of TIGIT and its ligands were characterized by flow cytometry and ELISA. TIGIT blockade was analyzed in in vitro functional assays with peripheral T cells. BM cells were studied with NanoString technology, real-time PCR, and ex vivo patient BM cell models. Results: TIGIT and its ligands are highly expressed in the BM of patients with multiple myeloma, suggesting that may play a role in restraining immune activation. TIGIT blockade depleted FoxP3+ Tregs while increasing proliferation of IFNγ-producing CD4+ T cells from patients with multiple myeloma. PVR ligation inhibited CD8+ T-cell signaling and cell proliferation which could be overcome with anti-TIGIT mAb. However, BM cells showed a remarkable heterogeneity in immune signature. Accordingly, functional ex vivo BM assays revealed that only some patients respond to checkpoint blockade. Thus, response to TIGIT blockade correlated with low frequency of TIGIT+ cells and high nectin-2 expression on malignant plasma cells. Conclusions: TIGIT blockade efficiently reinvigorated peripheral T cells from patients with multiple myeloma. However, in the BM, the efficacy of blocking anti-TIGIT mAb to achieve tumor cell death may depend on the expression of TIGIT and nectin-2, becoming potential predictive biomarkers for identifying patients who may benefit from TIGIT blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · cited 1×
“Patients were diagnosed according to standard International Myeloma Working Group criteria (33).”
MethodSelf-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921 · cited 1×
“The risk of progression from asymptomatic SMM to symptomatic disease is related to the proportion of BMPCs and the serum monoclonal protein level at diagnosis, among other prognostic factors (4, 5).”
BackgroundTIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., et al. (2018) · Blood · doi:10.1182/blood-2018-01-825265 · Cited by 300
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy
Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0933 · Cited by 223 · cited 2×
“Discussion Inhibitory checkpoint TIGIT has become an attractive target for cancer immunotherapy (28, 29).”
BackgroundT-cell costimulation–biology, therapeutic potential, and challenges.
Sharpe, A. H., & Abbas, A. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068087 · Cited by 206
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, B., Azpilikueta, A., Puig, N., Ocio, E. M., Sharma, R., Oyajobi, B. O., Labiano, S., San-Segundo, L., Rodriguez, A., Aires-Mejia, I., et al. (2015) · Leukemia · doi:10.1038/leu.2015.79 · Cited by 192 · cited 1×
“Furthermore, unlike PD-1, TIGIT was found highly expressed on NK cells in BM suggesting that TIGIT blockade could effectively activate NK-cell cytotoxicity in multiple myeloma (40).”
Background
Cited by
Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40
“In addition, some in vitro experiments found that low expression of TIGIT + cells and high expression of lectin-2 in malignant plasma cells directly affect TIGIT blockade [167].”
BackgroundPVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
Lee, B.-H., Kim, J.-H., Kang, K.-W., Lee, S.-R., Park, Y., Sung, H.-J., & Kim, B.-S. (2022) · Biomedicines · doi:10.3390/biomedicines10051099 · Cited by 19
“Additionally, previous studies reported that TIGIT exists as a soluble protein [11,36], and the present results showed that soluble TIGIT levels in plasma correlated with its expression in bone marrow CD8+ T cells and NK cells.”
BackgroundResult
Metadata
- Authors
- Lozano, E., Mena, M.-P., Díaz, T., Martin-Antonio, B., León, S., Rodríguez-Lobato, L.-G., Oliver-Caldés, A., Cibeira, M. T., Bladé, J., Prat, A., Rosiñol, L., & Fernández de Larrea, C.
- Venue
- Clinical Cancer Research
- Published
- 2020-09-01
- Volume
- 26
- Issue
- 17
- Pages
- 4688-4698
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3033064565
- Cited by
- 47
- References
- 7
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-3673
- The paper
- Lozano, E., Mena, M.-P., Díaz, T., Martin-Antonio, B., León, S., Rodríguez-Lobato, L.-G., Oliver-Caldés, A., Cibeira, M. T., Bladé, J., Prat, A., Rosiñol, L., & Fernández de Larrea, C. (2020). Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-3673
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.